Physician profile
Stuart N Thomas
NPI 1639125529
$2,212.78
in general payments reported to CMS, 2019-2025
25 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Plastic Surgery Within The Head & Neck provider received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $172 · 2021: $330 · 2022: $396 · 2023: $492 · 2024: $259 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $432.73 | 2022-2025 | |
| Optinose US, INC. | $316.33 | 2019-2025 | |
| Kaleo, INC. | $258.91 | 2020-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $175.14 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $149.95 | 2021-2025 | Dupixent |
| Cumberland Pharmaceuticals, INC. | $111.95 | 2023-2025 | Caldolor |
| Medtronic, INC. | $103.66 | 2023-2025 | Propel, Stealthstation S8 Platform |
| Stryker Corporation | $85.67 | 2019-2025 | Audion Et Dilation System |
| Arrinex, INC. | $76.19 | 2019 | |
| Alk-Abello, INC | $72.99 | 2019-2024 | Histamine Positive, Standardized Mite D. Farinae, Timothy, Standardized |
| Smith+Nephew, INC. | $58.04 | 2020-2024 | Tula |
| Glaxosmithkline, LLC. | $48.24 | 2024 | Nucala |
| Karl Storz Endoscopy-America | $47.19 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $41.15 | 2025 | Tezspire |
| Olympus America INC. | $30.68 | 2019-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.27 | 2021-2023 | |
| Acclarent, INC | $29.21 | 2022 | |
| Photonicare INC | $23.52 | 2023 | Otosight Middle Ear Scope |
| Aerin Medical INC. | $23.26 | 2024 | |
| Paratek Pharmaceuticals, INC. | $19.87 | 2025 | Xhance |
| Pfizer INC. | $19.40 | 2020 | |
| Amgen INC. | $16.02 | 2025 | Tezspire |
| Xoran Technologies LLC | $15.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.64 | 2022 | |
| Integra Lifesciences Corporation | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.